| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.04B | 2.71B | 2.51B | 3.90B | 9.90B | 5.77B |
| Gross Profit | 127.66M | 555.56M | -50.28M | 113.52M | 1.25B | 980.32M |
| EBITDA | -59.80M | 295.14M | -145.86M | -325.93M | 581.55M | 1.09B |
| Net Income | -1.41B | -1.24B | -563.97M | -912.78M | 228.33M | 98.74M |
Balance Sheet | ||||||
| Total Assets | 56.83B | 57.20B | 56.35B | 57.39B | 61.07B | 67.52B |
| Cash, Cash Equivalents and Short-Term Investments | 171.08M | 158.10M | 152.22M | 189.51M | 556.87M | 1.65B |
| Total Debt | 22.59B | 22.79B | 22.18B | 21.25B | 20.95B | 23.52B |
| Total Liabilities | 44.63B | 44.83B | 42.57B | 43.01B | 45.64B | 52.41B |
| Stockholders Equity | 9.70B | 9.93B | 11.17B | 11.73B | 12.71B | 12.49B |
Cash Flow | ||||||
| Free Cash Flow | 632.07M | 678.26M | 452.11M | 413.47M | 4.07B | 4.67B |
| Operating Cash Flow | 630.31M | 679.53M | 512.92M | 606.31M | 4.35B | 4.94B |
| Investing Cash Flow | 105.81M | 146.72M | 58.95M | -305.41M | 184.15M | -2.78B |
| Financing Cash Flow | -770.21M | -830.50M | -627.40M | -630.90M | -5.65B | -1.11B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | $2.17B | 12.19 | 3.79% | 4.94% | 3.15% | 1.96% | |
50 Neutral | HK$227.68M | ― | -5.13% | ― | -76.39% | -1142.86% | |
41 Neutral | HK$315.44M | ― | -34.31% | ― | -63.41% | 77.97% | |
40 Underperform | €157.24M | -0.01 | ― | ― | -70.13% | -16.86% | |
38 Underperform | HK$520.00M | ― | -13.99% | ― | -0.38% | -296.42% |
Glory Health Industry Limited has provided an update on its efforts to address a disclaimer of opinion issued by its auditors regarding its financial statements for the year ended December 31, 2024. The company has completed the Xi’an Guorui Financial Center Building, which is expected to aid in sales and cash flow recovery. Additionally, a significant loan extension has been approved, and the company is actively seeking buyers for several projects to ease liquidity problems and reduce debt. The management is committed to achieving debt restructuring and asset disposal goals within 2025.
Glory Health Industry Limited reported interim financial results for the six months ending June 30, 2025, revealing a challenging period with contracted sales of RMB651.1 million and property development revenue of RMB182.7 million, impacted by market conditions. The company experienced a total comprehensive loss of RMB170.019 million, attributed mainly to decreased revenue and increased expenses, highlighting ongoing pressures in the rental market and operational challenges.
Glory Health Industry Limited has announced a board meeting scheduled for August 29, 2025, to discuss and approve the unaudited interim results for the first half of 2025. The meeting will also consider the recommendation for an interim dividend payment, which could impact shareholder returns and market perception.